ACM
CSTL icon

AIGH Capital Management’s Castle Biosciences CSTL Stock Holding History

AIGH Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.5M Sell
590,601
-34,118
-5% -$1.12M 1.98% 13
2025
Q4 		$24.3M Sell
624,719
-82,568
-12% -$2.66M 5.88% 3
2025
Q3 		$16.1M Buy
+707,287
New +$14.4M 4.54% 8

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIGH Capital Management's CSTL Position: Q1 2026 in Review

AIGH Capital Management reduced its Castle Biosciences (CSTL) stake by 5.5% in Q1 2026, selling an estimated $1.12M and leaving 590,601 shares worth $14.5M. The position accounts for 1.98% of the portfolio, ranked #13.

AIGH Capital Management first reported a position in CSTL in Q3 2025 and has held it in 3 quarters since. The position peaked at $24.3M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • AIGH Capital Management held 590,601 shares of Castle Biosciences worth $14.5M as of Q1 2026.
  • AIGH Capital Management sold 34,118 Castle Biosciences shares in Q1 2026, an estimated $1.12M.
  • Castle Biosciences made up 1.98% of AIGH Capital Management's portfolio in Q1 2026, its #13 holding.
  • AIGH Capital Management first reported a position in Castle Biosciences in Q3 2025 and has held it in 3 quarters since.
  • AIGH Capital Management's Castle Biosciences position peaked at $24.3M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on AIGH Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.